Flezelastine

Flezelastine

SCHEMBL62291

O=c1c2ccccc2c(Cc2ccc(F)cc2)nn1C1CCCN(CCc2ccccc2)CC1

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 13/20 0.66
HRH1 P35367 13/20 0.66
ADRA1B P35368 13/20 0.66
HRH3 Q9Y5N1 8/20 0.66
ADRA2A P08913 2/20 0.60
CHRM1 P11229 2/20 0.60
ADRA2B P18089 2/20 0.60
HTR2A P28223 2/20 0.60
DRD3 P35462 2/20 0.60
ABCB1 P08183 2/20 0.60
KCNH2 Q12809 2/20 0.60
CHRM2 P08172 1/20 0.60
ADRB1 P08588 1/20 0.60
CYP2D6 P10635 1/20 0.60
GABRA1 P14867 1/20 0.60
ADRA2C P18825 1/20 0.60
SLC6A2 P23975 1/20 0.60
HTR2C P28335 1/20 0.60
SLC6A4 P31645 1/20 0.60
OPRM1 P35372 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flezelastine SCHEMBL29687099 1.00 ADRA1A (0.66) ADRA1AHRH1ADRA1BHRH3ADRA2A
Flezelastine SCHEMBL219748 0.99 ADRA1A (0.65) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL10372558 0.91 ADRA1A (0.79) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL10557080 0.90 ADRA1A (0.64) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL10766274 0.86 ADRA1A (0.65) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL2615138 0.85 HRH1 (0.81) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL2615137 0.85 HRH1 (0.81) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL10557572 0.83 ADRA1A (0.80) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL10375081 0.82 ADRA1A (0.75) ADRA1AHRH1ADRA1BHRH3ADRA2A
SCHEMBL10555618 0.81 ADRA1A (0.65) ADRA1AHRH1ADRA1BHRH3ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7488 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-11345956-B2 Methods and compositions related to prostate cancer therapeutics THE JOHNS HOPKINS UNIVERSITY (US) 2022-05-31 US claimed
US-11207289-B2 Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis ACADEMIA SINICA (TW) 2021-12-28 US claimed
US-10953073-B2 XTEN conjugate compositions and methods of making same AMUNIX PHARMACEUTICALS, INC. (US) 2021-03-23 US claimed
US-20210060040-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-03-04 US claimed
EP-3191114-B1 OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF UNIV MISSISSIPPI STATE (US) 2021-03-03 EP claimed
US-20200289454-A1 USE OF BENZOFURAN LIGNANS TO INDUCE IL-25 EXPRESSION AND SUPPRESS MAMMARY TUMOR METASTASIS Yang, Ning-Sun (TW) 2020-09-17 US claimed
US-20200270362-A1 MSLN TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE HARPOON THERAPEUTICS, INC. 2020-08-27 US claimed
US-20040092583-A1 Treatment for inhibiting neoplastic lesions SHANAHAN-PRENDERGAST ELIZABETH (IE) 2004-05-13 US claimed
EP-1351678-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS Shanahan-Prendergast, Elizabeth (IE) 2003-10-15 EP claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 WO claimed
EP-0888127-B1 COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS SEARLE & CO (US) 2001-12-12 EP claimed
EP-0659744-B1 Process of preparation of hexahydroazepinones and hexahydroazepinoles ASTA MEDICA AG (DE) 2001-02-28 EP claimed
US-5760221-A Method for the preparation of hexahydroazepinones and hexahydroazepinoles ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1998-06-02 US claimed
EP-0590551-B1 New therapeutic uses of phthalazinone-derivatives ASTA MEDICA AG (DE) 1996-10-30 EP claimed
US-5556856-A ANITARRHYTHMIA, ANALGESICS ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1996-09-17 US claimed
US-5536444-A Compressed-gas packages using polyoxyethylene glyceryl fatty-acid esters as suspension stabilizers and valve lubricants ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1996-07-16 US claimed